Baird notes Elevance Health (ELV) pre-announced a Q1 earnings beat with adjusted EPS of $11.97 vs. $11.62 implied guide, vs. $11.32 street, vs. its $11.63. The company cites medical costs developed in line with expectations including Medicare Advantage and although cost trends in MA remain elevated, Q1 experience was in line with expectations and pricing. The firm sees this Q1 print as quite positive for Elevance and in isolation would warrant a low single digit move higher today, but clearly quite a divergence from UnitedHealth’s (UNH) negative print today. Baird has a Neutral rating on Elevance with a price target of $529.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health Projects Q1 2025 Earnings Expectations
- Elevance Health backs FY25 adjusted EPS view of $34.15-$34.85, consensus $34.19
- Elevance Health sees Q1 adjusted EPS $11.97, consensus $11.38
- Morgan Stanley expects UnitedHealth shares to fall following guidance cut
- Nike initiated, GM downgraded: Wall Street’s top analyst calls